Article Review: Improving The Permeability of BCS Class II, III, and IV Drugs Using the Co-Amorph Method

Article Sidebar

pdf (Bahasa Indonesia)
Published: Feb 16, 2023
DOI: https://doi.org/10.36490/journal-jps.com.v6i1.68

Main Article Content

Vicania Raisa Rahman
Program Studi Profesi Apoteker, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Arif Budiman
Program Studi Profesi Apoteker, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.

Page: 307-314

Abstract

Drugs in the co-amorphous form are combinations of amorphous drugs with co-formers that have good solubility and stability so that dissolution becomes better and influences the therapeutic effect of drugs better, too the first time a co-amorphous formulation was made to overcome the low solubility of BCS class II. However, the current study found that co-amorphous formulations could improve solubility and the permeability of BCS class III and IV drugs. Co-amorphous production methods include cryo-milling, melting and quench cooling, solvent evaporation, and spray drying. This article review was conducted to gather information about BCS class II, III, and IV drugs made in co-amorphous forms to improve the physicochemical properties of drugs, such as solubility, permeability, and stability. Articles were collected from 20 research journals published over the last ten years. The co-amorphous drug testing of 10 drugs showed higher solubility and permeability than in crystal form

Downloads

Download data is not yet available.

Article Details

How to Cite
Rahman, V. R., & Budiman, A. (2023). Article Review: Improving The Permeability of BCS Class II, III, and IV Drugs Using the Co-Amorph Method. Journal of Pharmaceutical and Sciences, 6(1), 307–314. https://doi.org/10.36490/journal-jps.com.v6i1.68
Issue
JPS Volume 6 Nomor 1 (2023)
Section
Review Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

References

Aulton, M.E., dan Kelvin, M.G.T. 2018. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th Edition. UK: Elsevier.

Chavan RB, Thipparaboina R, Kumar D, Shastri NR. 2016. Co amorphous systems: A product development perspective. Int J Pharm. 515(1-2):403-415.

Chen X, Li D, Zhang H, Duan Y, Huang Y. 2021. Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: A strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis. Int J Pharm. 606:120894.

China Pharmaceutical University. 2013. A simvastatin-gliclazide co-amorphous compound. Available from: https://patents.google.com/patent/CN103360357A/en

China Pharmaceutical University. 2013. Carvedilol-asccharin amorphous compound. Available from: https://patents.google.com/patent/CN103467363A/en

China Pharmaceutical University. 2013. Irbesartan and repaglinide co-amorphous substance. Available from: https://patents.google.com/patent/CN103497178A/en?oq=CN103497178A

Dengale SJ, Grohganz H, Rades T, Löbmann K. 2016. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 100:116-25.

Hatanaka, Y., Uchiyama, H., Kadota, K., & Tozuka, Y. 2021. Improved solubility and permeability of both nifedipine and ketoconazole based on coamorphous formation with simultaneous dissolution behavior. Journal of Drug Delivery Science and Technology. 65: 102715.

Hebei Medical University. 2015. Azelnidipine-maleic acid co-amorphous substance and preparation method. Available from: https://patents.google.com/patent/CN104693181A/en

Hirakawa, Y., Hiroshi Ueda, Tetsuya Miyano, Noriho Kamiya, Masahiro Goto. 2019. New insight into transdermal drug delivery with supersaturated formulation based on co-amorphous system. International Journal of Pharmaceutics. 569: 118582.

Jana, S., dan Subrata, J. 2017. Particulate Technology for Delivery of Therapeutics. Singapore: Springer.

Jensen KT, Larsen FH, Löbmann K, Rades T, Grohganz H. 2016. Influence of variation in molar ratio on co-amorphous drug-amino acid systems. Eur J Pharm Biopharm. 107:32-9.

Karagianni, A., Kachrimanis, K., Nikolakakis, I. 2018. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 10(3):98.

Korhonen, Ossi., Pajula, K., Laitinen, R. 2016. Rational excipient selection for co-amorphous formulations. Expert Opinion on Drug Delivery. 14(4):551-569.

Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. 2013. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 453(1):65-79.

Löbmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon KC. 2013. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int J Pharm. 453(1):80-7.

MIMS. 2022. MIMS. Available from: https://www.mims.com/indonesia

Mizoguchi R, Waraya H, Hirakura Y. 2019. Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations. Mol Pharm. 16(5):2142-2152.

Prajapati, B., Indrani Maji, Rahul Kumar, Devendrasingh Tomar, Dharmendra Kumar Khatri, Jitender Madan, Pankaj Kumar Singh. 2022. Strategy to counteract the pyrazinamide induced hepatotoxicity by developing naringin based co-amorphous system with supplementary benefits. Journal of Drug Delivery Science and Technology. 69: 103181.

Ruponen M, Kettunen K, Santiago Pires M, Laitinen R. 2021. Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs. Pharmaceutics. 13(2):171.

Ruponen, M., Henna, R., dan Riikka, L. 2020. Dissolution and permeability properties of co-amorphous formulations of hydrochlorothiazide. Journal of Pharmaceutical Sciences. 109(7).

Setyawan, D., dan Diajeng, P. P. 2020. Strategi Peningkatan Kelarutan Bahan Aktif Farmasi. Surabaya: Airlangga University Press.

Sormunen H, Ruponen M, Laitinen R. 2019. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm. 570:118653.

Teja A, Musmade PB, Khade AB, Dengale SJ. 2015. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of talinolol with naringin: Solid state characterization, in-vivo in-situ evaluation. Eur J Pharm Sci. 78:234-44.

Tianjin Institute of Pharmaceutical Research Co Ltd. 2013. Co-amorphous system and preparation method. Available from: https://patents.google.com/patent/CN104415042A/en?oq=CN104415042A

Uppala, S., Sai Krishna Anand Vullendula, Dani Lakshman Yarlagadda, Swapnil Jayant Dengale. 2022. Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of fexofenadine. Journal of Drug Delivery Science and Technology. 72: 103431.

Wang, R., Jiawei Han, Ai Jiang, Rong Huang, Tingming Fu, Lingchong Wang, Qin Zheng, Wen Li, Junsong Li. 2019. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. International Journal of Pharmaceutics. 561: 9-18,

Wiergowska G, Ludowicz D, Wdowiak K, Miklaszewski A, Lewandowska K, Cielecka-Piontek J. 2021. Combinations of freeze-dried amorphous vardenafil hydrochloride with saccharides as a way to enhance dissolution rate and permeability. Pharmaceuticals. 14(5):453.

Wuhan Yuan Zhu Pharmaceutical Technology Co Ltd. 2014. Baicalein-caffeine amorphous compound. Available from: https://patents.google.com/patent/CN103923049A/en?oq=CN103923049A

Yu D, Kan Z, Shan F, Zang J, Zhou J. 2020. Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: enhancing water-solubility, permeability, and inhibiting cytochrome p450 isozymes. Mol Pharm. 17(12):4443-4462.